Literature DB >> 6233002

Inhibition by diphosphonates of bone resorption induced by the Walker tumor of the rat.

A Jung, J Bornand, B Mermillod, C Edouard, P J Meunier.   

Abstract

An animal model is described to test the effect of diphosphonates, which are powerful antiosteolytic agents, against bone tumors. This model consists of injecting Walker tumor cells into one iliac artery of a series of rats while the contralateral artery is clamped during the injection, and waiting 7 days to obtain a significant destruction of the femur and tibia of the rats. In most of the animals, after this delay, extensive lesions are observed macroscopically by X-ray and histologically. The parenteral administration of three diphosphonates, dichloromethylene diphosphonate, ethanehydroxydiphosphonate , and aminopropanediphosphonate , at 16 and 160 mumol/kg/day, protects the bones by decreasing the extent of osteolysis. This protective effect is seen both in the tumor-injected leg and in the contralateral leg and is significant when compared to nontreated animals. The most active of the drugs was dichloromethylene-diphosphonate; ethanehydroxydiphosphonate and aminopropanediphosphonate were less active, especially when given at the higher dosage. All diphosphonates produce a marked decrease of the number of osteoclasts; ethanehydroxydiphosphonate at the higher dosage, induced a large increase of nonmineralized bone. These results are discussed in light of recent clinical work, showing that this animal model is a useful tool to test the effect of new drugs against osteolysis of cancer.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6233002

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis.

Authors:  Andreas A Kurth; Soo-Zin Kim; Marie Shea; Frieder Bauss; Wilson C Hayes; Ralph Müller
Journal:  J Bone Miner Metab       Date:  2007-02-26       Impact factor: 2.626

Review 2.  [Introduction to bisphosphonates. History and functional mechanisms].

Authors:  H Fleisch
Journal:  Orthopade       Date:  2007-02       Impact factor: 1.087

Review 3.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 4.  Antitumour effects of bisphosphonates: first evidence and possible mechanisms.

Authors:  I J Diel
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

5.  The Walker 256/B carcinosarcoma in thyroparathyroidectomized rats: a model to evaluate inhibitors of bone resorption.

Authors:  R Rizzoli; H Fleisch
Journal:  Calcif Tissue Int       Date:  1987-10       Impact factor: 4.333

6.  Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice.

Authors:  M E Stearns; M Wang
Journal:  Clin Exp Metastasis       Date:  1998-11       Impact factor: 5.150

7.  In vitro effects of bone- and platelet-derived transforming growth factor-beta on the growth of Walker 256 carcinosarcoma cells.

Authors:  W Millar-Book; F W Orr; G Singh
Journal:  Clin Exp Metastasis       Date:  1990 Nov-Dec       Impact factor: 5.150

8.  Characterization of brain and bone-metastasizing clones selected from an ethylnitrosourea-induced rat mammary carcinoma.

Authors:  D G Hall; G Stoica
Journal:  Clin Exp Metastasis       Date:  1994-07       Impact factor: 5.150

9.  Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells.

Authors:  M E Stearns
Journal:  Clin Exp Metastasis       Date:  1998-05       Impact factor: 5.150

10.  Clodronate increases the calcium content in fracture callus. An experimental study in rats.

Authors:  M T Nyman; P Paavolainen; T S Lindholm
Journal:  Arch Orthop Trauma Surg       Date:  1993       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.